- Noramco Cannabinoids Business to Become Purisys
- Noramco at CPhI 2019
- Noramco at AAPS 2019
- Noramco at iCDP
- Say Hello to Amber Burch
- Say Hello to Gregory Moore
- Noramco Presents Comments and Answers Questions at FDA Hearing on Cannabidiol
- Noramco and Willow Biosciences Announce Joint Development of Biosynthesis Platform for Cannabidiol
- Say Hello to Elizabeth Abercrombie
- Nemus Bioscience Signs Agreement with Noramco
- Say Hello to Jackie Johnson
- Noramco at DCAT Week 2019
- Say Hello to Dan Hallow
- Say Hello to Nancy Bye
- Noramco at AAPS 2018
The Noramco Difference
Pharmaceutical companies trust Noramco to produce ultra-pure synthetic cannabinoid active ingredients that meet the strictest regulatory requirements of health authorities around the world. High capacity cGMP production facilities in Europe and the United States yield ultra-pure Cannabidiol (CBD), Dronabinol (THC), and Nabilone active ingredients.
For more than a decade Noramco has consistently delivered large volumes of Nal-family compounds and Buprenorphine HCI to the pharmaceutical industry. Noramco has made a long-term commitment to antagonist APIs, providing both the technologies and expertise pharmaceutical companies require to produce and commercialize addiction treatment and abuse prevention products (ATAP).
ADHD API Portfolio
Building out our ADHD capability for customers that want to work with us strategically throughout the ADHD range of technology, Noramco now offers a full range of APIs. ADHD focus products, an area which leverages our controlled substance expertise, and over a decade of supply, is an increasingly important technology platform within Noramco. Customers may call on us for high-quality Methylphenidate HCl, DexMethylphenidate, and Amphetamine Salts.